Description
The DPYD Test identifies patients with dihydropyrimidine dehydrogenase (DPD) deficiency, a genetic condition that affects the body’s ability to metabolize fluoropyrimidine chemotherapy drugs, such as 5-fluorouracil (5-FU) and capecitabine. Knowing a patient’s DPD status can help tailor cancer treatments to avoid severe toxic reactions.
TAT
4-6 business days
Method
PCR
Accepted Sample requirements
Peripheral Blood, DNA